The vocabulary of every pharmacy agreement, in plain English.

A compounding pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act. It compounds against prescriptions for identified individual patients, and in exchange is exempt from FDA new-drug approval, cGMP manufacturing rules, and certain labelling requirements. Its primary regulator is the state board of pharmacy.This is the pharmacy behind a patient-specific prescription shipped to a named patient — not the one that fills your treatment-room shelf.

A facility registered with the FDA under section 503B. It may compound without a patient-specific prescription, must comply with current good manufacturing practice, reports adverse events, and is subject to FDA inspection on a risk-based schedule.This is where compliant office stock comes from. If a supplier offers non-patient-specific product without being a registered 503B, that is the question to ask before the price question.

Any untoward medical occurrence associated with the use of a product, whether or not it is considered related.Document, treat, report. A clean internal record of what happened and when is the single most useful artefact if a claim follows.

A 503A pharmacy preparing limited quantities of a preparation before receiving a prescription, based on a documented history of receiving valid prescriptions for it.It shortens turnaround on your regular items. Ask a prospective pharmacy how they handle it — the answer tells you how predictable your lead times will be.

Testing for endotoxin — fragments of bacterial cell wall that can cause a febrile reaction even when a preparation is sterile.Sterile and endotoxin-free are two different claims. Both belong on the COA for an injectable.

The date or time after which a compounded preparation should not be used, assigned under USP standards based on the preparation, the compounding conditions, and storage. It is not the same thing as a manufacturer's expiration date, which is supported by stability testing on a manufactured product.Short BUDs on sterile preparations are the hidden cost of an otherwise cheap per-unit price. Ask for the BUD before you compare quotes.

A product derived from living sources — cells, tissues, proteins — regulated under a distinct pathway from small-molecule drugs, generally requiring a licensed biologics application.The regulatory pathway is different, which is why “it is just a biologic” is never a compliance answer.

The active ingredient used in compounding. A 503A pharmacy may use a bulk substance that has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list — and it must come from an FDA-registered establishment with a certificate of analysis. A 503B facility may generally use a bulk substance only if it is on FDA's 503B bulks list or appears on the drug shortage list.“We can source the API” is not the same statement as “we may lawfully compound with it.” Ask which list, in writing.

A document from the testing laboratory reporting the results for a specific lot — identity, potency or assay, and where applicable sterility and endotoxin.Demand it per lot, not per product. A COA for a different lot proves nothing about the vial in your hand.

The temperature-controlled handling and shipping required to keep a temperature-sensitive product within its labelled storage range from the pharmacy to administration.Ask what happens when a shipment arrives warm, and who eats the cost. Get it in the agreement, not the sales call.

A written agreement between a physician and a nurse practitioner or physician assistant setting out the scope, protocols, and review arrangements for the non-physician's practice, where the state requires one.In reduced and restricted states this is the document that lets your NP practise. It is also a recurring cost and a single point of failure — plan for the day the collaborating physician resigns.

The practice of combining, mixing, or altering drug ingredients to create a medication tailored to an individual patient. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness, or manufacturing quality before they reach a patient.Everything else in this glossary hangs off that one fact. When a vendor says a product is “pharmacy grade,” ask what that means in statute — the answer is nothing.

The doctrine, applied with varying force by state, that a corporation or unlicensed individual may not employ a physician to practise medicine or control clinical decision-making.It is the reason a non-physician owner in a strict state ends up in an MSO structure. Check your state on the compliance map and take the structure to a healthcare attorney.

The FDA's manufacturing quality framework covering facilities, equipment, process controls, testing, and records. 503B outsourcing facilities must comply; 503A pharmacies are exempt from it.“cGMP” on a 503A's marketing material is a claim worth asking about, because the exemption is the whole point of 503A.

A licensed practitioner authorising a qualified individual to perform a task the delegator is authorised to perform, with defined supervision. What may be delegated, to whom, and under what supervision is state-specific.The chain from prescriber to injector is where most staffing plans meet their first real constraint.

The National Association of Boards of Pharmacy accreditation programme for wholesale distributors, formerly known as VAWD.A useful screen on any distributor selling you injectables or devices with drug components.

The 2013 federal law enacted after a 2012 fungal meningitis outbreak traced to a compounding pharmacy. It clarified FDA authority over compounding under section 503A and created the 503B outsourcing facility category, with FDA registration, cGMP compliance, and federal inspection.It is why the 503A/503B distinction exists at all, and why it is the first question to ask a pharmacy partner.

FDA's published list of drugs in shortage. Shortage status interacts with the “essentially a copy” limits, and can change what compounded versions may lawfully be prepared.When a drug leaves the shortage list, the compounded landscape around it can change quickly. Build a program that survives that.

Federal requirements for tracing prescription drug products through the supply chain, including transaction records and verification of trading partners.It is the basis for asking any distributor to prove where a product came from — the defence against diverted or counterfeit inventory.

A statutory limit on compounding. A 503A pharmacy generally may not compound a drug that is essentially a copy of a commercially available product unless the prescriber determines a change makes a significant difference for that patient. A 503B facility generally may not compound a drug that is essentially a copy of an approved drug, with exceptions including drugs on the FDA shortage list.This single concept drives most of the churn in what compounded products are available in a given year — including in weight management.

Any non-active component of a preparation — the diluent, preservative, buffer, or vehicle.Preservative choice drives beyond-use dating on multi-dose vials, which drives how much waste you carry.

A small membrane-bound vesicle released by cells. FDA has publicly cautioned about unapproved products of this type, and no exosome product is approved for aesthetic indications.If you use them, the documentation you demand per lot is your defence. Our exosome compliance guide lists what to require.

The federal statute governing drugs, devices, and cosmetics, including sections 503A and 503B on compounding.When a contract cites “503A” or “503B,” it is citing sections of this act.

An evaluation of the patient by an appropriately licensed professional, establishing the treatment plan, before treatment is provided. Requirements — who may perform it, whether it may be done by telehealth, and how often it must be repeated — are set by state law and board rules.The most commonly cited deficiency in med spa enforcement actions. Check your state on the compliance map, then check it again after any change of protocol.

Products containing or derived from human cells or tissue. Some qualify for regulation solely under section 361 of the Public Health Service Act when they meet strict criteria including minimal manipulation and homologous use; products falling outside those criteria are regulated as drugs or biologics requiring FDA approval.The “361 exemption” is claimed far more often than it applies. Ask the supplier to state in writing which pathway their product is on.

The other core 361 criterion: the product performs the same basic function in the recipient as it did in the donor.Aesthetic applications frequently fail this test, which is where a great many marketing claims quietly break.

The documented process of disclosing the nature of a treatment, its risks, benefits, and alternatives, and obtaining the patient's agreement.For off-label or compounded therapies, the disclosure that the product is not FDA-approved belongs in the document in plain language.

A third-party certification widely used by payment processors and advertising platforms to verify that a healthcare merchant meets their standards.Practical consequence: it often decides whether you can run ads or process payments for certain services at all.

The identifier tying a specific unit of product to the batch it was made in, its testing, and its recall status.Log it in the chart at the point of administration. If a recall lands, that log is the difference between five phone calls and five hundred.

An entity that provides non-clinical services — premises, staff, billing, marketing, administration — to a professional practice under a management services agreement, while clinical decisions remain with the licensed practice.The common structure for non-physician ownership in CPOM states. How the agreement is drafted is the difference between compliant and merely common.

The licensed physician responsible for clinical oversight of a practice — protocols, delegation, quality, and in many arrangements the supervisory relationship for non-physician providers.The role is a real clinical responsibility, not a name on a wall. Our guide to coverage in all 50 states covers the structures and the ownership language to insist on.

The FDA's programme for reporting adverse events and product quality problems for drugs, biologics, and devices.Know how to file before you need to. Documented reporting is part of a defensible response to a bad outcome.

One of the criteria for the 361 HCT/P pathway: processing that does not alter the original relevant characteristics of the tissue.Processing that concentrates, expands, or reformulates typically takes a product outside the exemption.

Compounding of preparations not required to be sterile — capsules, creams, oral liquids — under USP General Chapter <795>.Relevant to topical and oral adjuncts in an aesthetics or wellness menu.

The license a pharmacy must hold to ship into a state where it is not physically located.Verify it for every state you treat patients in, and re-verify it — licenses lapse quietly.

A licensed prescriber using an FDA-approved product for an indication, population, or route other than the one on its approved labelling. It is lawful and common in medical practice; promotion of off-label uses is regulated separately.Off-label use of an approved drug and use of a compounded, non-approved preparation are different things. Do not let a vendor blur them.

Medication kept at the practice for administration to whichever patient presents, rather than dispensed against a named prescription. Whether a practice may hold office stock, and from whom, is governed by both federal compounding law and state pharmacy rules.Same-day, in-office treatment depends on it. State rules on office use vary more than most owners expect, so verify before building a service around it.

A prescription written for a named, identified patient by a licensed prescriber — the legal basis on which a 503A pharmacy compounds.It is why a telehealth-plus-503A model ships to the patient's door but does not stock your cabinet.

A voluntary compounding-pharmacy accreditation programme administered by ACHC, involving standards review and on-site survey.Voluntary, so its presence is a signal and its absence is a question — not a verdict either way.

A short chain of amino acids. Regulatory status varies entirely by the specific substance: some are components of approved drugs, some sit on FDA bulk substance lists, some are on neither.Never reason about “peptides” as a category. The question is always which substance, on which list, from which pharmacy.

Analytical testing establishing how much active ingredient a preparation actually contains, against label claim.Under-potent product looks like a clinical failure and gets blamed on the provider.

A corporate form restricted to licensed professionals. A “friendly” PC is one owned by a licensed physician who contracts with an MSO for administrative services.Ask who owns the PC, what happens if that physician leaves, and whether that succession is documented.

Coverage for claims arising from professional services. Aesthetic and wellness services, compounded therapies, and device treatments are not automatically included in a general policy.Read the exclusions for compounded products and elective cosmetic procedures before you assume you are covered.

Removal or correction of a marketed product. Compounded preparations can be and are recalled, most often for sterility assurance or potency concerns.Ask a prospective pharmacy for its recall history and how it notified customers. The answer is more informative than any brochure.

A labelling category for products intended for laboratory research and not for administration to humans.An RUO label is not a technicality. Product bought under it and given to a patient is the clearest line in this entire glossary.

The federal law governing prescribing of controlled substances via the internet, generally requiring at least one in-person medical evaluation subject to specific telemedicine exceptions. DEA has issued temporary telemedicine flexibilities and extended them more than once.If any part of your menu is a controlled substance, verify the current DEA position before building a workflow on it — this is an area that has moved repeatedly.

What a given license permits its holder to do, defined by the state's practice act and board rules.It governs who may inject, who may assess, and who may operate a given device — and device rules sometimes differ from injectable rules in the same state.

The level of care a reasonably prudent practitioner with similar training would provide under similar circumstances.It is the yardstick in a malpractice claim, and it is not lowered by a patient's signature on a consent form.

A written instruction from a physician authorising specified personnel to perform defined tasks for patients meeting stated criteria, where state law allows.Where permitted, it does not replace a good faith exam — the two are frequently confused in enforcement actions.

The state agency licensing pharmacies and pharmacists and setting rules on compounding, office use, and dispensing within that state.The board in your patient's state matters as much as the board in the pharmacy's state.

Compounding of preparations intended to be sterile — injectables, infusions, ophthalmics — performed under the standards in USP General Chapter <797>, which govern the environment, personnel training, testing, and beyond-use dating.Everything you inject falls here. It is the single largest determinant of a compounding pharmacy's real quality posture.

Laboratory testing establishing that a preparation intended to be sterile is free of viable microorganisms.Ask whether it is performed per lot or per batch cycle, and who holds the results.

The required availability of the supervising practitioner — on premises, immediately reachable, or generally available — defined by state law and often varying by procedure.“Available by phone” is a legal category in some states and unacceptable in others. Verify the definition, not the vibe.

Prescribing following an evaluation conducted by telecommunication rather than in person. Rules differ by state, by drug schedule, and by whether the prescriber-patient relationship already exists.For controlled substances, federal law adds a separate layer on top of state rules — see the Ryan Haight Act.

The USP general chapter covering safe handling of hazardous drugs in healthcare settings — receipt, storage, compounding, administration, and disposal.Mostly a pharmacy question, but it becomes yours the moment a hazardous drug is administered or stored on your premises.